{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-061212","form_type":"8-K","ticker":"MNKD","cik":"0000899460","company_name":"MANNKIND CORP","filed_at":"2021-12-27T23:59:59+00:00","discovered_at":"2026-05-14T18:04:16.144579+00:00","generated_at":"2026-06-27T22:27:40.730999+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"medium","headline":"United Therapeutics resubmits Tyvaso DPI NDA to FDA after CRL","bullets":["UT received a Complete Response Letter from FDA on Oct 18, 2021 for Tyvaso DPI.","UT disclosed on Dec 27, 2021 that it has resubmitted the NDA to FDA.","Tyvaso DPI uses MannKind's Inhalation technology; resubmission is a key regulatory milestone."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-061212","json":"https://secwatch.observer/filing/0001564590-21-061212.json","markdown":"https://secwatch.observer/filing/0001564590-21-061212.md","text":"https://secwatch.observer/filing/0001564590-21-061212.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/899460/000156459021061212/0001564590-21-061212-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/899460/000156459021061212/mnkd-8k_20211227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T22:27:40.730999+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}